Business
Covance to Present Affimer Data at Conference
Covance to Present Affimer Data at Conference.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 4911W Avacta Group PLC 15 November 2017 \n\n \n \n15 November 2017\n \nAvacta Group plc\n(\"Avacta\", \"the Group\" or \"the Company\")\n \nCovance to Present Affimer Data at European Conference \n \n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum 15-17 November 2017 in Barcelona. \n \nCovance will be presenting data that highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement. \n \nThe work carried out collaboratively between Avacta and Covance shows that an Affimer assay to detect and quantify the breast cancer drug Trastuzumab shows good sensitivity and increased assay dynamic range compared to current existing antibody based assays. \n \nThe study demonstrates that Affimer reagents have the potential to be used as alternatives to antibodies and natural ligands as critical reagents in regulated assays in the development and batch release of therapeutic antibodies. \n \nDr Alastair Smith, Avacta Group Chief Executive Officer, commented:\n\"Presentation of Affimer data by our partners is strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology. The Group is delighted that the results of this work will be presented at this important European conference by Covance, a global contract research organization that that has worked on all of the top 50 best-selling drugs available today. \n \nReagents such as antibodies or ligand proteins, currently used in regulated bioanalysis of therapeutic proteins have their limitations. Cost and batch-to-batch variability is a serious and costly issue in critical assays. The work with Covance shows that Affimers can provide a rapid solution in such assays and additionally benefit from stability of supply. \n \nWe are now working to capitalise on the commercial opportunity that this presents and I look forward to updating the market on progress in due course.\" \n \n\n\n \nFor further information from Avacta Group...